Literature DB >> 9225898

En bloc pancreaticoduodenectomy and colectomy for duodenal neoplasms.

M J Edwards1, K Nakagawa, K M McMasters.   

Abstract

Duodenal malignancy is rare and generally considered to have both a low resectability rate and a poor prognosis. Historically, the involvement of the colon or its mesentery has been considered a criterion for unresectability by many surgeons because of the overall magnitude of surgery involved with an en bloc colectomy and pancreaticoduodenectomy. In the past few years, several reports have noted a decrease in morbidity and mortality rates for pancreaticoduodenectomy. The current safety of the procedure suggests that the classical criteria for resectability can now be reevaluated for certain neoplasms. We report two cases of pancreaticoduodenectomy with en bloc colectomy done as attempted curative resections for primary duodenal malignancies. The procedure was well tolerated by both patients; there were no major complications, and it provided both prolonged survival and effective palliation.

Entities:  

Mesh:

Year:  1997        PMID: 9225898     DOI: 10.1097/00007611-199707000-00017

Source DB:  PubMed          Journal:  South Med J        ISSN: 0038-4348            Impact factor:   0.954


  3 in total

1.  Resection of the colon simultaneously with pancreaticoduodenectomy for tumors of the pancreas and periampullary region: short-term and long-term results.

Authors:  Yasuyuki Suzuki; Yasuhiro Fujino; Yasuki Tanioka; Tetsuya Sakai; Tetsuo Ajiki; Takashi Ueda; Masahiro Tominaga; Yoshikazu Kuroda
Journal:  World J Surg       Date:  2004-09-29       Impact factor: 3.352

2.  Increased morbidity and mortality of a concomitant colectomy during a pancreaticoduodenectomy: an NSQIP propensity-score matched analysis.

Authors:  Jennifer W Harris; Jeremiah T Martin; Erin C Maynard; Patrick C McGrath; Ching-Wei D Tzeng
Journal:  HPB (Oxford)       Date:  2015-07-30       Impact factor: 3.647

3.  Combined pancreaticoduodenectomy and extended right hemicolectomy: outcomes and indications.

Authors:  Eric T Kimchi; Mehrdad Nikfarjam; Niraj J Gusani; Diego M Avella; Kevin F Staveley-O'Carroll
Journal:  HPB (Oxford)       Date:  2009-11       Impact factor: 3.647

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.